PR Newswire BiotechOriginal article
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
Data ReadoutpositiveProSense®Positive
AI Analysis
Summary
IceCure announced two new peer-reviewed publications supporting cryoablation for breast cancer treatment de-escalation, highlighting FDA marketing authorization of ProSense®, updated American Society of Breast Surgeons guidelines, and five-year ICE3 clinical trial outcomes. The publications extend cryoablation's clinical applications to axillary lymph node treatment.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Five-year ICE3 clinical trial results supporting cryoablation in breast cancer treatment de-escalation; two peer-reviewed publications highlighting FDA marketing authorization and updated American Society of Breast Surgeons guidelines
Importance:6/10
Sentiment:
0.70
cryoablationbreast cancerFDA authorizationclinical trialpublicationsde-escalationaxillary lymph nodes
Related Companies
Read the original article
Published by PR Newswire Biotech on August 13, 2026 1:10 PM